Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer

[1] Khorana AA(2016)Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 2541-2556

[2] Mangu PB(2016)Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 2784-2796

[3] Berlin J(2016)Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 2654-2668

[4] Engebretson A(2015)Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Drug Des Devel Ther 9 4479-4499

[5] Hong TS(2015)First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma Clin Cancer Res 21 553-560

[6] Maitra A(2014)A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 32 Abstract LBA173-1152

[7] Mohile SG(2015)Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 76 1143-1130

[8] Mumber M(2000)TGF-β/SMAD signaling and its involvement in tumor progression Biol Pharm Bull 23 1125-840

[9] Schulick R(2008)LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol Cancer Ther 7 829-247

[10] Shapiro M(2004)TGF-beta2 suppression in pancreatic cancer by the antisense oligonucleotide AP 12009: preclinical efficacy data Proc Am Assoc Cancer Res 45 Abstract 2955-undefined

[1] Khorana AA(2016)Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 2541-2556

[2] Mangu PB(2016)Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 2784-2796

[3] Berlin J(2016)Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline J Clin Oncol 34 2654-2668

[4] Engebretson A(2015)Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Drug Des Devel Ther 9 4479-4499

[5] Hong TS(2015)First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma Clin Cancer Res 21 553-560

[6] Maitra A(2014)A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 32 Abstract LBA173-1152

[7] Mohile SG(2015)Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 76 1143-1130

[8] Mumber M(2000)TGF-β/SMAD signaling and its involvement in tumor progression Biol Pharm Bull 23 1125-840

[9] Schulick R(2008)LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis Mol Cancer Ther 7 829-247

[10] Shapiro M(2004)TGF-beta2 suppression in pancreatic cancer by the antisense oligonucleotide AP 12009: preclinical efficacy data Proc Am Assoc Cancer Res 45 Abstract 2955-undefined